Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Geneva, Switzerland, June 30, 2025, STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs. This financing underscores investor confidence in Stalicla's innovative DEPI precision neuro platform and its portfolio of precision autism assets, STP1 and STP2. The company is also progressing its STP7 (mavoglurant) program, the most clinically advanced mGluR5 negative allosteric modulator, having concluded a Phase 3 enabling drug-drug interaction study in October 2024. The Phase 3 development continues to be financed by National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) under a Collaborative Research and Development Agreement.As part of this financing, Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman. 

"This financing is a key step in securing our runway to reach a number of important ...